Cervicitis. Chlamydial infection of lower genitourinary tract
Conditions
Interventions
Intervention 1: Intervention group: 1 vial of 10 mL royal jelly rogit from Biotech company, used alongside standard treatment consisting of 1 gram of azithromycin (single oral dose) and 400 mg of cefi
Sponsors
Arak University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
17 Years to 45 Years
Inclusion criteria
Inclusion criteria: Women with cervicitis married status ages 17–45 years with recurrent cervicitis as defined in the study willingness to participate in the study
Exclusion criteria
Exclusion criteria: No recurrence of infection in the first 3 months of illness before starting treatment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cervical bleeding. Timepoint: Once during the first three months at the time of detecting recurrence, and once at the end of the second three-month follow-up period, the amount of cervical bleeding is examined. Method of measurement: Clinical examination: Amount of cervical bleeding: Bleeding may appear as spotting, bleeding during examination, or continuous cervical bleeding. During the examination, it will be assessed and recorded in terms of severity, frequency, and its relation to mechanical stimulation (such as palpation of the cervix with a speculum). | — |
Secondary
| Measure | Time frame |
|---|---|
| Cervical inflammation. Timepoint: Once at the time of detecting disease recurrence after the first three months, and once at the end of the second three-month follow-up period, the level of cervical inflammation is examined. Method of measurement: Clinical examination: Cervical inflammation is assessed in terms of redness, swelling, tenderness to palpation, and the presence of local inflammatory signs such as purulent discharge and superficial lesions. The severity of inflammation will be scored according to standard criteria for gynecologic examinations.;Cervical discharge. Timepoint: Once at the time of detecting disease recurrence in the first three months, and once at the end of the second three-month follow-up period, the amount of cervical discharge is examined. Method of measurement: Clinical examination: Cervical secretions/ Discharge: At this stage, the characteristics of abnormal secretions will be assessed in terms of color (white, yellow, green), consistency (thin or thick), quantity, and foul odor. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMahla sadat saremi
Arak University of Medical Sciences
Outcome results
None listed